Search results

Abstract Radiotherapy is a cornerstone of cancer treatment and is currently administered to approximately half of all cancer patients. However, the cytotoxic effects of ionizing radiation on normal tissues represent a major limitation, as they restrict the dose that can be safely delivered to patients and, consequently, reduce the likelihood of effective tumor control. In this context, delivering radiation at ultra-high dose rates (UHDR, > 40 Gy/s) is gaining increasing attention due to its potential to spare healthy tissues surrounding the tumor and to prevent radiation-induced side effects, as compared to conventional dose rates (CONV, on the order of Gy/min).The mechanism underlying this protective effect-termed the FLASH effect-remains elusive, driving intensive research to elucidate the biological processes triggered by this type of irradiation.In vitro models offer a valuable tool to support this research, allowing for the efficient screening of various beam parameters and biological responses in a time- and cost-effective manner. In this study, multicellular tumor spheroids and normal cells were exposed to proton irradiation at UHDR to evaluate its efficacy in controlling tumor growth and its cytotoxic impact on healthy tissues, respectively.We report that UHDR and CONV irradiation induced a comparable growth delay in 3D tumor spheroids, suggesting similar efficacy in tumor control. In normal cells, both dose rates induced similar levels of senescence; however, UHDR irradiation led to lower apoptosis induction at clinically relevant doses and early time points post-irradiation.Taken together, these findings further highlight the potential of UHDR irradiation to modulate the response of normal tissues while maintaining comparable tumor control.JuryProf. Thomas BALLIGAND (UNamur), PresidentProf. Stéphane LUCAS (UNamur), SecretaryProf. Carine MICHIELS (UNamur)Dr Sébastien PENNINCKX (Hôpital Universitaire de Bruxelles)Prof. Cristian FERNANDEZ (University of Bern)Dr Rudi LABARBE (IBA)

In 1996, the European Union created the Marie Skłodowska-Curie Actions (MSCA), a set of prestigious and competitive grants designed to fund research. Thanks to her, the PROSTAMET project got underway on January 1, an ambitious program focused on training PhD students and discovering new therapeutic avenues against prostate cancer, in which UNamur is participating.

Stanford University has published a prestigious ranking that highlights the most influential researchers in a wide range of scientific fields. The list, based on bibliographic criteria, aims to provide a standardized means of identifying the world's scientific leaders. It is one criterion among others for assessing the quality of scientific research. Twelve researchers from the University of Namur are among them!

The TineaDiag project is a research project run by UNamur and ULiège with funding from the SPW Research Win²WAL program. It tackles dermatophytoses, skin infections responsible for ringworm, which can affect both humans and animals. The aim? To identify, in dermatophytes, precise cellular markers in order to detect them with sensitivity and certainty, and thus identify infections caused by antifungal-resistant strains.

A major breakthrough for the health of women on oral contraceptives has been achieved by researchers in Namur. Every year in Europe, more than 22,000 cases of venous thrombosis or embolism occur among contraceptive pill users. A team of researchers from the University of Namur, in collaboration with QUALIblood (spin-off), has conducted an important study, the results of which could transform prescribing recommendations..

In late November, the Mont-Saint-Guibert-based company Cellistic® donated equipment it no longer used to UNamur. By enabling the university to give this equipment a second life, Cellistic is making an important gesture in support of the development of university research.

Bringing a new drug to market, particularly when it is intended to treat a pediatric or orphan disease, is a journey fraught with pitfalls. The ERAMET project, coordinated by Professor Flora Musuamba Tshinanu, aims to overhaul the assessment procedures, so that regulatory agencies can take innovative technologies into account and thus make more informed choices.

Founded some 50 years ago, the Laboratoire d'Analyse par Réactions Nucléaires (LARN) in the Department of Physics at the University of Namur is home to a 2MV tandem particle gas pedal named ALTAÏS (Accélérateur Linéaire Tandetron pour l'Analyse et l'Implantation des Solides), in operation since 1999.

The three Belgian scientific experiments selected to be carried out on board the International Space Station (ISS) during astronaut Raphaël Liégeois' mission in 2026 have just been unveiled by the Federal Science Policy Public Service (Belspo). One of them is carried by a team from UNamur for an experiment at the crossroads of biology and physics aimed at analyzing the resistance of the "blob", an atypical unicellular organism.

Researchers from UNamur's Departments of Biology and Physics have conducted a scientific experiment to assess the radioresistance of the common black ant Lasius niger. The results of their work have just been published in the Belgian scientific journal Belgian Journal of Zoology. The Namur-based scientists demonstrate a level of resistance far superior to that of humans. Their spontaneous approach also demonstrates a lesser-known approach to scientific research.

Beautiful victory for Margaux Mignolet, a researcher at the Faculty of Medicine's Unité de Recherche en Physiologie Moléculaire (URPhyM), who wins 1st prize in the Belgian inter-university final of the Ma thèse en 180 secondes (MT180) competition. Her research? To better understand the mechanisms of antibodies active in cases of long COVID. The second prize in this national competition was also won by a candidate from Namur. It was Petra Manja, from the Unité de Recherche en biologie des micro-organismes (URBM), Department of Biology, Faculty of Science, and is pursuing a thesis aimed at understanding resistance mechanisms in the bacterium E. coli. Both are also researchers at the NARILIS Institute.

Hepatocellular carcinoma is the most common primary liver cancer. Unfortunately, this tumor still has a high mortality rate due to the lack of effective treatments for its most advanced or poorly localized forms. As part of a partnership with the CHU UCL Namur - site de Godinne and with the support of Roche Belgium, researchers in the Department of Biomedical Sciences are trying to understand why liver tumor cells are so resistant to treatment, and to identify therapeutic alternatives to better target them.